ATNM

NYSEAMERICAN 已收盘

Actinium Pharmaceuticals

1.05 USD
▼-0.02-1.87%
盘后 1.06 0.00%
2026-11-20
市值
$33.01M
市盈率
3.10
EPS
0.34
股息率
—
52 周区间
0.74 – 1.72
成交量
280.91K
Beta
0.26
目标价
4.50
52W 低 0.7452W 高 1.72
价格走势

公司简介

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody...